The Role of Peptide YY (PYY)in Inhibiting Food Intake.
Not Applicable
Completed
- Conditions
- Obesity
- Registration Number
- NCT00259233
- Lead Sponsor
- University of Copenhagen
- Brief Summary
12 obese subjects will receive peripheral administration of placebo and 4 escalating doses of PYY1-36 and another 12 obese subjects will receive peripheral administration of placebo and 4 escalating doses PYY3-36 on 5 different test days within one week. The patients will be tested in a single blinded dose escalating protocol. Measurements of appetite, ad libitum energy intake, blood pressure and blood sampling will be performed during the test day.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 24
Inclusion Criteria
- Normal weight (BMI: 18-23 kg/m2) or 12 overweight/obese (BMI: 27-40 kg/m2)
- Body weight fluctuations < 5 kg over the past 2 months.
- Blood pressure normal to mildly hypertensive(<159/99 mm Hg)
- Non-elite athletes and not planning to change physical activity during the study.
Exclusion Criteria
- Any physiological or psychological illnesses that could influence the study results.
- Regular use of medicine.
- Smoking defined as <1 cigarette per day.
- Substance abuse or dependence.
- Blood donation within the past 3 months before entering the study.
- Drinking >21 alcoholic units/week.
- Food allergies.
- Special diets (e.g. vegetarian) or dislikes to any of the foods served during the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method appetite energy intake
- Secondary Outcome Measures
Name Time Method Plasma PYY profile Blood pressure